Serum levels of total and urine level of PCA3 in patients with benign prostatic hyperplasia and prostate cancer.

Urine test with the PSA result will provide a good prognosis of the prostate cancer. Therefore, considering the importance of PCA3 in this study, we aimed to compare the serum total and urinary PCA3 levels in patients with benign hyperplasia and prostate cancer.

This cross-sectional study was performed on 90 patients referring to Noor and Hazrat-e-Ali Asghar Hospital in Isfahan from October 2017 to October 2018 for prostate biopsy. Patients were divided into two groups including benign prostate hyperplasia (BPH) and prostate cancer. Serum total and urinary PCA3 levels were measured and compared in both groups.

38 patients with prostate cancer and 52 patients with BPH participated in this study. Mean age in prostate cancer group was significantly higher than BPH group (P=0.01). Also mean PCA3, and total PSA, in patients with prostate cancer was significantly higher than patients with BPH (P<0.05).

PCA3 was an important marker in patients with prostate cancer and BPH.

American journal of clinical and experimental urology. 2020 Feb 25*** epublish ***

Mozhde Askari, Amid Yazdani, Mohammad Yazdani, Mohammad Hossein Izadpanahi

School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran., Department of Orology, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.